Ipsen S.A. (IPSEY) Discusses Phase II LANTIC Data and Innovation in Engineered Neuroinhibitors for Aesthetic Indications - Slideshow
Ipsen S.A. recently presented data from its Phase II LANTIC study, focusing on engineered neuroinhibitors for aesthetic applications. The presentation included insights into the innovation behind these neuroinhibitors. This event highlights Ipsen's ongoing commitment to advancing aesthetic medicine.
- ▪Ipsen S.A. discussed its Phase II LANTIC data during a recent presentation.
- ▪The focus of the study is on engineered neuroinhibitors for aesthetic indications.
- ▪The slide deck published by Ipsen provides insights into their innovative approaches.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4906233-ipsen-s-a-ipsey-discusses-phase-ii-lantic-data-and-innovation-in-engineered-neuroinhibitors"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
